Clinical trial · Interventional
Effects of Dexmedetomidine During IRE Procedures for Solid Tumours
Effects of Dexmedetomidine on Anaesthesia During IRE Procedures for Solid Tumours
NCT02044224CI-TRIAL-00019532completedPhase 4ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of the study is to evaluate effects of dexmedetomidine on anaesthesia during IRE procedures for solid tumours
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Cancer of Liver | Malignant Liver Neoplasm | ALIAS | 0.90 |
| Cancer of Pancreas | Malignant Pancreatic Neoplasm | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Dexmedetomidine | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Dexmedetomidine
- description
- Dexmedetomidine infusion during anaesthesia for IRE procedure
- interventionNames
- Drug: Dexmedetomidine
Primary outcomes (1)
- measure
- Patient Satisfaction With Anaesthesia Technique
- timeFrame
- At the discharge from post-anaesthesia care room (up to 4 hours after the procedure)
- description
- Rating of how satisfied the patient was with their sedation on a scale of 1-5 with 1 being very dissatisfied and 5 being extreme
Secondary outcomes (5)
- measure
- Evaluation of anaesthetic consumption
- timeFrame
- During anaesthesia
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 85 Years
Show eligibility criteria text
Inclusion Criteria: 1. liver or/and pancreas cancer for which IRE procedure is planned 2. signed informed consent form Exclusion Criteria: 1. patient refusal 2. pregnancy 3. known allergy to dexmedetomidine or other anaesthesia drugs 4. atrioventricular block grade II or III or other significant cardiac conduction disturbance 5. stroke 6. low blood pressure not responding to treatment
References
Publications (5)
- BACKGROUNDJones CR. Perioperative uses of dexmedetomidine. Int Anesthesiol Clin. 2013 Spring;51(2):81-96. doi: 10.1097/AIA.0b013e31828d58c7. No abstract available. PMID 23532129
- BACKGROUNDYazbek-Karam VG, Aouad MM. Perioperative uses of dexmedetomidine. Middle East J Anaesthesiol. 2006 Oct;18(6):1043-58. No abstract available. PMID 17263262
- BACKGROUNDBarletta JF, Miedema SL, Wiseman D, Heiser JC, McAllen KJ. Impact of dexmedetomidine on analgesic requirements in patients after cardiac surgery in a fast-track recovery room setting. Pharmacotherapy. 2009 Dec;29(12):1427-32. doi: 10.1592/phco.29.12.1427. PMID 19947802
- BACKGROUNDCheung W, Kavnoudias H, Roberts S, Szkandera B, Kemp W, Thomson KR. Irreversible electroporation for unresectable hepatocellular carcinoma: initial experience and review of safety and outcomes. Technol Cancer Res Treat. 2013 Jun;12(3):233-41. doi: 10.7785/tcrt.2012.500317. Epub 2013 Jan 25. PMID 23369152
- BACKGROUNDBall C, Thomson KR, Kavnoudias H. Irreversible electroporation: a new challenge in "out of operating theater" anesthesia. Anesth Analg. 2010 May 1;110(5):1305-9. doi: 10.1213/ANE.0b013e3181d27b30. Epub 2010 Feb 8. PMID 20142349